<DOC>
	<DOCNO>NCT01558115</DOCNO>
	<brief_summary>Primary hyperparathyroidism ( PHPT ) , disease characterize excess parathyroid hormone ( PTH ) high blood calcium , one common endocrine disorder . PHPT see often postmenopausal woman . Many patient PHPT low bone mineral density ( BMD ) bone mass measure dual energy x-ray absorptiometry ( DXA ) , primarily forearm . There currently effective medical therapy increase bone density forearm patient PHPT . PTH build break bone , pathways PTH mediates action begin identify . Prior research suggest RANKL , molecule important bone metabolism , respond PTH , RANKL inactivate , PTH shift towards build bone . The investigator study effect Denosumab , therapeutic agent bind inactivate RANKL , 28 postmenopausal woman PHPT . Our hypothesis Denosumab increase bone mineral density primary hyperparathyroidism . The study last two year , subject randomly assign receive either placebo Denosumab first year study . In second year , subject receive Denosumab . Denosumab ( 60 mg ) placebo give every 6 month injection skin . Study procedures perform include bone mineral density test DXA , high-resolution peripheral quantitative compute tomography ( HR-pQCT ) scan , assessment biochemical marker calcium metabolism bone turnover use blood urine sample subject PHPT .</brief_summary>
	<brief_title>Denosumab Primary Hyperparathyroidism</brief_title>
	<detailed_description>PTH catabolic anabolic property , normal circumstance , PTH PHPT catabolic bone cortical skeleton . Recently , evidence direct role PTH RANKL expression osteoclastogenesis vivo obtain use mouse lack distant transcriptional enhancer RANKL gene confers responsiveness PTH . These observation , support additional cross-sectional study human subject make compelling argument catabolic action PTH mediate RANKL-mediated bone resorption . The investigator propose proof concept study test hypothesis PHPT , inhibition RANK-L pathway unmask anabolic potential PTH . A therapeutic agent redirects action PTH PHPT one primarily catabolic anabolic one would fulfill proof concept . The investigator hypothesize Denosumab , human IgG antibody bind inactivate RANKL , convert skeletal action PTH catabolic anabolic primary hyperparathyroidism .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Confirmed hypercalcemic PHPT postmenopausal woman serum calcium &gt; 10.2 mg/dL &lt; 12.0 mg/dL ( nl : 8.610.2 ) Tscore 1.5 2.5 site . If Tscore &lt; 2.5 , patient become candidate parathyroid surgery . They enrol refuse parathyroid surgery 25hydroxyvitamin D level &lt; 20 ng/ml Previous use bisphosphonate zoledronic acid ( ever ) , alendronate risedronate ( within 12 month ) ibandronate ( within 6 month ) Current use PTH , glucocorticoid , SERMS , estrogen ( vaginal ) , calcitonin pharmacological amount calcitriol Current previous use cinacalcet ( within 6 month ) Hyperthyroidism Rheumatoid arthritis inflammatory joint disease Paget 's disease bone Malabsorption Tscore &lt; 3.5 site Signs symptomatic PHPT ( e.g , kidney stone within past 5 year ; fragility fracture within past 2 year ) Physical mental handicap condition precludes ability complete protocol and/or provide inform consent . Subjects Antiviral HIV therapy subject compromise immune system Premenopausal woman men Stage 5 CKD anyone dialysis Creatinine clearance &lt; 30 cc/min unless patient candidate surgery patient refuse surgery</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Columbia University</keyword>
	<keyword>Primary hyperparathyroidism</keyword>
	<keyword>Low bone density</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Prolia</keyword>
</DOC>